Today, the European Commission (the Commission) started a market test inviting comments from interested parties on commitments offered by Aspen Pharmacare Holdings (Aspen) to address the Commission's concerns over excessive pricing for a range of off-patent cancer medicines (see, attached Commission press release). Broadly, Aspen’s proposed commitments are the following: a) Applying a price
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.